Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DICER1 antisense RNA 1 (non-protein coding) (DICER1-AS1)
- Target
- DICER1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
DICER1 antisense RNA 1 (DICER1-AS1) is a long non-coding RNA transcribed antisense to the DICER1 gene. It does not encode a protein but regulates gene expression at the post-transcriptional level by interacting with microRNAs (such as miR-34a-5p and miR-650). DICER1-AS1 acts as a competing endogenous RNA (ceRNA), influencing the levels and activity of specific miRNAs, and thereby modulating the expression of downstream target genes involved in cell cycle, apoptosis, drug resistance, and cellular metabolism. It has been implicated in the suppression of cell proliferation and migration in gastric and pancreatic cancer, and in chemotherapy drug resistance in osteosarcoma. Due to its regulatory roles in tumor biology, DICER1-AS1 is studied mainly as a functional RNA in cancer research rather than as a direct therapeutic drug target.
- Other names
- FLJ45244DICER1-ASDICER1 antisense RNA (non-protein coding)DICER1 antisense RNA 1 (non-protein coding)
02
Mechanism of action
Drugs modulate responses in cells with altered DICER1-AS1 levels, affecting drug resistance/sensitivity. Regulates resistance to chemotherapeutic agents by modulating apoptosis and cell cycle arrest.
03
Biological functions
Competes with microRNAs (miRNAs) by acting as a competing endogenous RNA (ceRNA)Regulates DICER1 expression and, through it, the production of miRNAsModulates cell cycle and apoptosisRegulates drug resistance and cellular responses to stress in cancer cellsInvolved in metabolic processes, e.g., glycolysis suppression in pancreatic cancer
04
Disease associations
Cancer (e.g., osteosarcoma, gastric cancer, pancreatic cancer)Tumor suppression or modulation of tumor-related processes
05
Safety considerations
Modulating lncRNAs for therapy is challenging due to off-target effects, delivery, and tissue specificity (general to lncRNA targeting; not specifically cited in these sources)
06
Interacting drugs
Etoposide
4 more in the full profile.
07
Biomarkers
DICER1-AS1 expression (potential biomarker for cancer drug resistance or prognosis)
Beyond the preview
Go deeper on DICER1 antisense RNA 1 (non-protein coding) (DICER1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DICER1 antisense RNA 1 (non-protein coding) (DICER1-AS1).